Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Advertorial: Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy? The triad of inflammation, neuropathy, and vasculopathy plays a key role ...

Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Researcher Adam Dubis, PhD, from John A. Moran Eye Center, is playing a role in the use of artificial intelligence (AI) in eye care. 1 Dubis co-founded German-based health tech company deepeye Medical ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova with an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).

A recent study reveals cannabis use may lower the risk of proliferative vitreoretinopathy after retinal detachment repair, suggesting potential therapeutic benefits.

The diabetic macular edema section is a comprehensive resource for Ophthalmology news and expert insights. Read more at Modern Retina.